WHO WE ARE
We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.
Our lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine has recently been selected by the Sean M. Healey & AMG Center for ALS at Mass General Hospital, as of the first four potential new treatments to be included in the launch of the first ever Platform Trial in Amyotrophic lateral sclerosis. The trial design aims to accelerate the development of effective treatments for people living with ALS, by testing and evaluating multiple treatments simultaneously. The choice of Pridopidine was in a global competition involving >30 applications.
In addition to the Healey platform trial, Prilenia is planning to initiate a phase 3 trial in Huntington Disease in the near future. Pridopidine is the first drug to show a statistically significant effect on maintenance of functional capacity in early HD, as measured by Total Functional Capacity (TFC) in a clinical trial. Currently there is no approved treatment for functional decline in HD. Only two drugs are approved for relieving certain motor symptoms.
Pridopidine is currently in Phase 2 trial for the treatment of patients with Parkinson’s Disease suffering from Levodopa Induced Dyskinesia (PD-LID).